No Data
No Data
Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch
Citi Downgrades BioAge Labs(BIOA.US) to Hold Rating, Cuts Target Price to $7
Morgan Stanley Downgrades BioAge Labs(BIOA.US) to Sell Rating, Cuts Target Price to $5
BioAge Labs Faces Sell Rating Amid Safety Concerns and Uncertain Prospects
BioAge Labs: Strategic Shifts and Developmental Progress Support Hold Rating Amidst Inherent Risks
BioAge Labs Terminates Azelapra Development
Fortune Smiles 88 : what has to do with BIOA?